Nature Communications (Nov 2023)

Epidermal growth factor receptor activation is essential for kidney fibrosis development

  • Shirong Cao,
  • Yu Pan,
  • Andrew S. Terker,
  • Juan Pablo Arroyo Ornelas,
  • Yinqiu Wang,
  • Jiaqi Tang,
  • Aolei Niu,
  • Sarah Abu Kar,
  • Mengdi Jiang,
  • Wentian Luo,
  • Xinyu Dong,
  • Xiaofeng Fan,
  • Suwan Wang,
  • Matthew H. Wilson,
  • Agnes Fogo,
  • Ming-Zhi Zhang,
  • Raymond C. Harris

DOI
https://doi.org/10.1038/s41467-023-43226-x
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Fibrosis is the progressive accumulation of excess extracellular matrix and can cause organ failure. Fibrosis can affect nearly every organ including kidney and there is no specific treatment currently. Although Epidermal Growth Factor Receptor (EGFR) signaling pathway has been implicated in development of kidney fibrosis, underlying mechanisms by which EGFR itself mediates kidney fibrosis have not been elucidated. We find that EGFR expression increases in interstitial myofibroblasts in human and mouse fibrotic kidneys. Selective EGFR deletion in the fibroblast/pericyte population inhibits interstitial fibrosis in response to unilateral ureteral obstruction, ischemia or nephrotoxins. In vivo and in vitro studies and single-nucleus RNA sequencing analysis demonstrate that EGFR activation does not induce myofibroblast transformation but is necessary for the initial pericyte/fibroblast migration and proliferation prior to subsequent myofibroblast transformation by TGF-ß or other profibrotic factors. These findings may also provide insight into development of fibrosis in other organs and in other conditions.